– CANADA, Vancouver – Ondine Biomedical, Inc. today announced that The Honourable Jean Charest and Joseph Sowell, III have been appointed to Ondine’s Board of Directors.
Mr. Charest is currently a partner in the law firm McCarthy Tetrault in the Montreal office and serves as an advisor to Canada’s Ecofiscal Commission.
“We are pleased and honoured that The Honourable Jean Charest has joined our Board of Directors,” said Carolyn Cross, CEO and Chairman, Ondine Biomedical Inc. “From his focus on reforming Canadian health care – in particular reducing hospital wait times – to his extensive experience in public policy and international business, Mr. Charest represents a Canadian icon who continues to champion better outcomes for global citizens.”
“Having worked with infectious disease outbreaks in Quebec hospitals during the early part of my career, recruiting financial support for better outcomes and improving administrative policy to better prepare Canada to face emerging challenges to human health, I have long been deeply concerned about the threat of multi-drug resistance,” stated Mr. Charest. “Ondine’s non-antibiotic technology represents a new and dynamic approach to prevention and treatment of infections, bringing new light to the rapidly growing problem of antibiotic resistance. I am happy to play a role in helping to bring this important new technology to patients within and beyond Canadian borders.”
Joseph Sowell is the Senior Vice President and Chief Development Officer of Nashville, TN based HCA Healthcare, Inc., and is responsible for all development functions and transactions related to HCA’s investment, acquisition, or divestiture of any business, including hospitals, outpatient centers, and physician practices. Mr. Sowell is an active supporter of numerous Nashville charitable and nonprofit organizations, including St. Luke’s Community House and Room In the Inn – Campus for Human Development.
“We are pleased and excited that Mr. Sowell has joined our Board of Directors,” said Carolyn Cross, CEO and Chairman, Ondine Biomedical Inc. “Mr. Sowell has an impressive background in the healthcare industry and a keen understanding of the challenges facing patients and healthcare organizations due to infections and multi-drug resistance. We are looking forward to working with Mr. Sowell and benefiting from his extensive experience and ongoing support.”
“I am impressed with Ondine’s technology and the results they have been able to achieve through their work across the globe with leading physicians, hospitals and infection control specialists. I am honored to join Ondine’s Board,” said Mr. Sowell. “Ondine is tackling this global challenge in public health with innovative solutions and a progressive approach, and I look forward to contributing to their efforts to tackle multi-drug resistance and improving patient outcomes.”
Mrs Charest and Sowell join the board with a new board member, Vicente Fox, Former President of Mexico (2000 – 2006).
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. Ondine’s platform technology is called Photodisinfection, a patented light activated technology that provides rapid antimicrobial efficacy without encouraging antibiotic resistance. Ondine’s lead product is the MRSAid™ nasal decolonization system which is used to safely decolonize the nose of a broad spectrum of pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and fungi. Several next-generation products in the hospital-associated infection (HAI) and Chronic Sinusitis markets are currently under development.
For more information : http://www.ondinebio.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.